

Docket: 7218.07

0300  
#6

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Named Inventor:	Charles N. Serhan	Examiner:  Group Art Unit:
Application No.:	10/044,449	
Filing Date:	January 11, 2002	
Title:	Inhibition of TNF-a-Initiated Neutrophil Response	

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR 1.97(b)Commissioner for Patents  
Washington, D.C. 20231I hereby certify that this document is being sent via First Class U. S. mail addressed to: Commissioner for Patents, Washington, D.C. 20231 on this 5<sup>th</sup> day of APRIL, 2002.  
(Signature)


Dear Sir:


Pursuant to 37 CFR 1.97(b), the references listed on the attached Form PTO-1449 (3 sheets, submitted in duplicate) are brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. This IDS is being filed within three months of the filing date of the application. In accordance with 37 CFR 1.97(b), no statement or fee is required.

Copies of the references cited are not enclosed, as allowed under 37 CFR 1.98(d). Each item on the enclosed Form PTO-1449 was cited to, or cited by, the Office in the prior related case, 09/525,291, filed March 14, 2000, to which priority to an earlier effective filing date is claimed under 35 U.S.C. § 120, in the present application.

Respectfully submitted,

DORSEY &amp; WHITNEY LLP

Date: April 5, 2002By:   
Scott D. Rothenberger (Reg. No. 41,277)  
Suite 1500  
50 South Sixth Street  
Minneapolis, Minnesota 55402-1498  
Telephone: 612-340-8819

Form PTO-1449  
(Rev. 8-83)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO:  
7218.07APPLICATION NO:  
10/044,449

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

APPLICANT(S):  
Charles N. SerhanFILING DATE:  
January 11, 2002

GROUP ART UNIT:

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE*
AA	5 4 4 1 9 5 1	8/15/95	Serhan	514	213	

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AB	WO 94/29262	12/22/94	PCT	C07C	69/732		
	AC	WO 95/01179	01/12/95	PCT	A61K	31/557		
	AD	WO 98/11049	03/19/98	PCT	C07C	59/42		

## OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

AE	Serhan, C.N., J.Z. Haeggström, and C.C. Leslie. 1996. Lipid mediator networks in cell signaling: update and impact of cytokines. <i>FASEB J.</i> 10:1147-1158
AF	Weiss, S.J. 1989. Tissue destruction by neutrophils. <i>N. Engl. J. Med.</i> 320:365-376
AG	Marucha, P.T., R.A. Zeff, and D.L. Kreutzer. 1991. Cytokine-induced IL-1 $\beta$ gene expression in the human polymorphonuclear leukocyte: transcriptional and post-transcriptional regulation by tumor necrosis factor and IL-1. <i>J. Immunol.</i> 147:2603-2608
AH	Lloyd, A.R., and J.J. Oppenheim. 1992. Poly's lament: the neglected role of the polymorphonuclear neutrophil in the afferent limb of the immune response. <i>Immunology Today</i> 13:169-172
AI	Hachicha, M., P.H. Naccache, and S.R. McColl. 1995. Inflammatory microcrystals differentially regulate the secretion of macrophage inflammatory protein 1 and interleukin-8 by human neutrophils: A possible mechanism of neutrophil recruitment to sites of inflammation in synovitis. <i>J. Exp. Med.</i> 182:2019-2025
AJ	Hansen, P.R. 1995. Role of neutrophils in myocardial ischemia and reperfusion. <i>Circulation</i> 91:1872-1885
AK	Takano, T., S. Fiore, J.F. Maddox, H.R. Brady, N.A. Petasis, and C.N. Serhan. 1997. Aspirin-triggered 15-epi-lipoxin A <sub>4</sub> and LXA <sub>4</sub> stable analogs are potent inhibitors of acute inflammation: Evidence for anti-inflammatory receptors. <i>J. Exp. Med.</i> 185:1693-1704
AL	Clària, J., and C.N. Serhan. 1995. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. <i>Proc. Natl. Acad. Sci. USA</i> 92:9475-9479
AM	Lee, T.H., C.E. Horton, U. Kyan-Aung, D. Haskard, A.E. Crea, and B.W. Spur. 1989. Lipoxin A <sub>4</sub> and lipoxin B <sub>4</sub> inhibit chemotactic responses of human neutrophils stimulated by leukotriene B <sub>4</sub> and N-formyl-L-methionyl-L-leucyl-L-phenylalanine. <i>Clin. Sci.</i> 77:195-203
AN	Serhan, C.N. 1994. Lipoxin biosynthesis and its impact in inflammatory and vascular events. <i>Biochim. Biophys. Acta</i> 1212:1-25

AO	Papayianni, A., C.N. Serhan, M.L. Phillips, H.G. Rennke, and H.R. Brady. 1995. Transcellular biosynthesis of lipoxin A <sub>4</sub> during adhesion of platelets and neutrophils in experimental immune complex glomerulonephritis. <i>Kidney Int.</i> 47:1295-1302
AP	Chavis, C., I. Vachier, P. Chanez, J. Bousquet, and P. Godard. 1996. 5(S),15(S)-Dihydroxyeicosatetraenoic acid and lipoxin generation in human polymorphonuclear cells: dual specificity of 5-lipoxygenase towards endogenous and exogenous precursors. <i>J. Exp. Med.</i> 183:1633-1643
AQ	Thomas, E., J.L. Leroux, F. Blotman, and C. Chavis. 1995. Conversion of endogenous arachidonic acid to 5,15-diHETE and lipoxins by polymorphonuclear cells from patients with rheumatoid arthritis. <i>Inflamm. Res.</i> 44:121-124
AR	Serhan, C.N., J.F. Maddox, N.A. Petasis, I. Akritopoulou-Zanze, A. Papayianni, H.R. Brady, S.P. Colgan, and J.L. Madara. 1995. Design of lipoxin A <sub>4</sub> stable analogs that block transmigration and adhesion of human neutrophils. <i>Biochemistry</i> 34:14609-14615
AS	Gronert, K., S.P. Colgan, and C.N. Serhan. 1998. Characterization of human neutrophil and endothelial cell ligand-operated extracellular acidification rate by microphysiometry: impact of reoxygenation. <i>J. Pharmacol. Exp. Ther.</i> 285:252-261
AT	Tessier, P.A., P.H. Naccache, I. Clark-Lewis, R.P. Gladue, K.S. Neote, and S.R. McColl. 1997. Chemokine networks in vivo: involvement of C-X-C and C-C chemokines in neutrophil extravasation in vivo in response to TNF- $\alpha$ . <i>J. Immunol.</i> 159:3595-3602
AU	Tsuji, M., S. Kawano, S. Tsuji, H. Sawaoka, M. Hori, and R.N. DuBois. 1998. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. <i>Cell</i> 93:705-716
AV	Shibuya, H., N. Ohkohchi, S. Tsukamoto, and S. Satomi. 1997. Tumor necrosis factor-induced, superoxide-mediated neutrophil accumulation in cold ischemic/reperfused rat liver. <i>Hepatology</i> 26:113-120
AW	Jaeschke, H., A. Farhood, and C.W. Smith. 1990. Neutrophils contribute to ischemia/reperfusion injury in rat liver <i>in vivo</i> . <i>FASEB J.</i> 4:3355-3359
AX	Dinareello, C.A. 1996. Biologic basis for interleukin-1 in disease. <i>Blood</i> 87:2095-2147
AY	Fiore, S., and C.N. Serhan. 1995. Lipoxin A <sub>4</sub> receptor activation is distinct from that of the formyl peptide receptor in myeloid cells: inhibition of CD11/18 expression by lipoxin A <sub>4</sub> -lipoxin A <sub>4</sub> receptor interaction. <i>Biochemistry</i> 34:16678-16686
AZ	Sin, Y.M., A.D. Sedgwick, E.P. Chea, and D.A. Willoughby. 1986. Mast cells in newly formed lining tissue during acute inflammation: a six day air pouch model in the mouse. <i>Ann. Rheum. Dis.</i> 45:873-877
BA	Maddox, J.F., M. Hachicha, T. Takano, N.A. Petasis, V.V. Fokin, and C.N. Serhan. 1997. Lipoxin A <sub>4</sub> stable analogs are potent mimetics that stimulate human monocytes and THP-1 cells via a G-protein linked lipoxin A <sub>4</sub> receptor. <i>J. Biol. Chem.</i> 272:6972-6978
BB	Isomaki, P., and J. Punnonen. 1997. Pro- and anti-inflammatory cytokines in rheumatoid arthritis. <i>Ann. Med.</i> 29:499-507
BC	Volpert, O.V., T. Fong, A.E. Koch, J.D. Peterson, C. Waltenbaugh, R.I. Tepper, and N.P. Bouck. 1998. Inhibition of angiogenesis by interleukin 4. <i>J. Exp. Med.</i> 188:1039-1046.
BD	Moreland, L.W., S.W. Baumgartner, M.H. Schiff, E.A. Tindall, R.M. Fleischmann, A.L. Weaver, R.E. Ettlinger, S. Cohen, W.J. Koopman, K. Mohler, M.B. Widmer, and C.M. Blosch. 1997. Treatment of reumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. <i>N. Engl. J. Med.</i> 337:141-147
BE	Marriott, J.B., M. Westby, and A.G. Dalgleish. 1997. Therapeutic potential of TNF- $\alpha$ inhibitors old and new. <i>DDT</i> 2:273-282
BF	Saleem, S., Z. Dai, S.N. Coelho, B.T. Konieczny, K.J.M. Assmann, F.K. Baddoura, and F.G. Lakkis. 1998. IL-4 is an endogenous inhibitor of neutrophil influx and subsequent pathology in acute antibody-mediated inflammation. <i>J. Immunol.</i> 160:979-984.

	BG	Lehn, M., W.Y. Weiser, S. Engelhorn, S. Gillis, and H.G. Remold. 1989. IL-4 inhibits H <sub>2</sub> O <sub>2</sub> production and antileishmanial capacity of human cultured monocytes mediated by IFN- $\gamma$ . <i>J. Immunol.</i> 143:3020-3024
	BH	Takano, et al., Neutrophil-Mediated Changes in Permeability are Inhibited by Topical Application of Aspirin-Triggered 15-ept-Lipoxin A4 and Novel Lipoxin B4 Stable Analogs, <i>Journal of Clinical Investigations</i> , Vol. 101, No. 4, pgs. 819-826 (2/98)
	BI	Gewirtz, et al., Pathogen-Induced Chemokine Secretion from Model Intestinal Epithelium is Inhibited by Lipoxin A4 Analogs, <i>Journal of Clinical Investigations</i> , Vol. 101, No. 9, pgs. 1860-1869 (5/98)
	BJ	International Search Report, July 17, 2000
Examiner		Date Considered:
		*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and considered. Include copy of this form with next communication to applicant.